Valuation check: AZN.ST's profit margin is 17.02%, above the Healthcare sector average of 9.48%.
Get informed when a big investor buys or sells
+ FollowAs of Jun 2026
Trailing 12 months ending Jun 2026
The latest profit margin for AZN.ST is 17.02% as of June 2026. That compares with 14.81% in the prior-year period — up 14.9% year over year. That is above the Healthcare sector average of 9.48%. Investors often review this figure alongside AstraZeneca PLC's historical trend and sector peers before judging valuation or financial health.
Over the past year, AZN.ST's profit margin moved from 14.81% to 17.02% — a 14.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in AstraZeneca PLC's valuation or profitability profile.
Against Healthcare companies, AZN.ST currently prints 17.02% for profit margin, while the sector average sits near 9.48%. That is roughly 79.5% above the sector mean. Large gaps often invite a closer look at AstraZeneca PLC's growth, margins, and balance sheet.
Profit Margin shows how effectively AstraZeneca PLC converts resources into returns. At 17.02%, AZN.ST may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 14.81% in the prior-year period — up 14.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting AZN.ST's profit margin (17.02%), review year-over-year change from 14.81%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.